First human test begins for new Alpha-1 treatment
NCT ID NCT07193615
Summary
This is a very early study to check if a new treatment called YOLT-202 is safe for people with Alpha-1 Antitrypsin Deficiency (AATD). It will involve 18 adults with a specific genetic form of the disease. The main goal is to find a safe and effective single dose, not to cure the condition, and participants will be followed for a full year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ren Ji Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, China
Conditions
Explore the condition pages connected to this study.